“The presentations at EASD continue to reinforce the efficacy and safety
of BYETTA and the promise of exenatide once weekly as a potential new
treatment option for patients with type 2 diabetes,” stated Orville G.
Kolterman, M.D., senior vice president of research and development,
Key exenatide abstracts for EASD 2009 include:
Clinical Trial Data
-
Poster: Presentation #729,
Sept. 30 ,1:45-2:45 p.m. CEST
“Effects of Exenatide plus Rosiglitazone on Measures of Beta Cell Function and Insulin Sensitivity in Subjects with Type 2 Diabetes Previously Treated With Metformin” will be presented byLeonard Glass , M.D.
-
Poster: Presentation #730,
Sept. 30 ,1:45-2:45 p.m. CEST
“Exenatide Once Weekly Treatment Elicits Sustained Glycaemic Control and Weight Loss Over 2 Years” will be presented byMichael Trautmann , M.D.
-
Poster: Presentation #739,
Oct. 1 ,12:45-1:45 p.m. CEST
“DURATION-2: Exenatide Once Weekly Demonstrated Superior Glycemic Control and Weight Reduction Compared to Sitagliptin or Pioglitazone After 26 Weeks of Treatment” will be presented byCarol Wysham , M.D.
-
Poster: Presentation #795,
Oct. 1 ,12:45-1:45 p.m. CEST
“Changes in Adipokines in Type 2 Diabetic Patients Treated with Exenatide versus Glimepiride on Metformin Background – Results of a Prospective, Randomized Controlled Study Over 9 Months” will be presented byBaptist Gallwitz , M.D.
Safety Assessments
-
Oral: Presentation #6,
Sept. 30 ,12:15-12:30 p.m. CEST
“Incidence of Acute Pancreatitis in Exenatide Initiators Compared to Other Antidiabetic Drug Initiators: A Retrospective, Cohort Study” will be presented byGary Bloomgren , M.D.
-
Poster: Presentation #758,
Oct. 2 ,12:45-1:45 p.m. CEST
“Exenatide Once Weekly Improved Cardiometabolic Risk Factors in Subjects with Type 2 Diabetes During One Year of Treatment” will be presented by Richard Bergenstal, M.D.
-
Poster: Presentation #759,
Oct. 2 ,12:45-1:45 p.m. CEST
“Cardiovascular Safety of Exenatide BID: An Integrated-Analysis from Long-Term Controlled Clinical Trials in Subjects with Type 2 Diabetes” will be presented byLarry Shen , Ph.D.
-
Poster: Presentation #768,
Oct. 2 ,1:45-2:45 p.m. CEST
“Safety and Tolerability of Exenatide BID in Patients With Type 2 Diabetes: Integrated Analysis of 3854 Patients From 11 Comparator Controlled Clinical Trials” will be presented byMatthew Wintle , M.D.
Patient-Reported Outcomes
-
Poster: Abstract Presentation #745,
Oct. 1 ,12:45-1:45 p.m. CEST
“DURATION 2: Weight-Related Quality of Life, Psychological Well-Being, and Satisfaction with Exenatide Once Weekly Compared to Sitagliptin or Pioglitazone After 26 Weeks of Treatment” will be presented byJennie Best , Ph.D.
About BYETTA® (exenatide) Injection
BYETTA is the first and only
Important Safety Information for BYETTA
BYETTA is not a substitute for insulin in patients whose diabetes requires insulin treatment. BYETTA is not recommended for use in patients with severe problems digesting food or those who have severe disease of the stomach or kidney.
When BYETTA is used with a medicine that contains a sulfonylurea, hypoglycemia (low blood sugar) is a possible side effect. To reduce this possibility, the dose of sulfonylurea medicine may need to be reduced while using BYETTA. Other common side effects with BYETTA include nausea, vomiting, diarrhea, dizziness, headache, feeling jittery, and acid stomach. Nausea is the most common side effect when first starting BYETTA, but decreases over time in most patients.
If patients experience the following severe and persistent symptoms (alone or in combination): abdominal pain, nausea, vomiting, or diarrhea, they should talk to their healthcare provider because these symptoms could be signs of serious medical conditions. BYETTA may reduce appetite, the amount of food eaten, and body weight. No changes in dose are needed for these side effects. These are not all of the side effects from use of BYETTA. A healthcare provider should be consulted about any side effect that is bothersome or does not go away.
For full prescribing information, visit www.BYETTA.com.
About Diabetes
Diabetes affects approximately 24 million people in the U.S. and an
estimated 246 million adults worldwide.(i,ii) Approximately 90-95
percent of affected adults have type 2 diabetes. Diabetes is the fifth
leading cause of death by disease in the U.S. and results in
approximately
According to the
About Amylin, Lilly and
Amylin, Lilly and
Through a long-standing commitment to diabetes care, Lilly provides patients with breakthrough treatments that enable them to live longer, healthier and fuller lives. Since 1923, Lilly has been the industry leader in pioneering therapies to help healthcare professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients.
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research
from its own worldwide laboratories and from collaborations with eminent
scientific organizations. Headquartered in
This press release contains forward-looking statements about Amylin,
Lilly and
P-LLY
(i) "All About Diabetes."
(ii) The International Diabetes Federation Diabetes Atlas. Available at: http://www.idf.org/home/index.cfm?unode=3B96906B-C026-2FD3-87B73F80BC22682A.
Accessed
(iii) "Direct and Indirect Costs of Diabetes in
(iv) Saydah SH, Fradkin J and Cowie CC. "Poor control of risk factors
for vascular disease among adults with previously diagnosed diabetes." JAMA:
291(3),
(v) Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract. 2007;61:737-47.
(vi) Nutrition Recommendations and Interventions for Diabetes: a
position statement of the
(vii) Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr. 2003;22:331-9.
Source:
Amylin
Anne Erickson, 858-754-4443
Cell:
858-349-3195
anne.erickson@amylin.com
or
Lilly
Kindra
Strupp, 317-277-5170
Cell: 317-554-9577
kstrupp@lilly.com
or
Alkermes
Rebecca
Peterson, 617-583-6378
Cell: 617-899-2447
rebecca.peterson@alkermes.com